Glizid-MV Gliclazide Metformin Hydrochloride Voglibose Tablets

Glizid-MV Tablets – Triple Combination Therapy for Effective Type 2 Diabetes Control

Glizid-MV Tablets are an advanced oral anti-diabetic medication that combines Gliclazide, Metformin, and Voglibose to provide comprehensive blood sugar management in patients with Type 2 Diabetes Mellitus. This triple-action formulation helps control both fasting and postprandial glucose levels, improving overall glycemic stability and reducing diabetes-related complications.

Glizid-MV is a scientifically balanced combination that targets different aspects of blood glucose regulation:

• Gliclazide – A sulfonylurea that stimulates pancreatic beta cells to increase insulin secretion.

• Metformin Hydrochloride – A biguanide that reduces hepatic glucose production and enhances insulin sensitivity.

• Voglibose – An alpha-glucosidase inhibitor that delays glucose absorption in the intestine, reducing post-meal sugar spikes.

Together, these agents ensure better glycemic control, lower HbA1c levels, and sustained diabetes management.

• Triple-action formula for superior blood sugar regulation

• Controls both fasting and post-meal glucose levels

• Reduces insulin resistance and improves pancreatic response

• Helps prevent diabetes-related complications

• Improves metabolic balance and weight management

• Ideal for patients with poorly controlled Type 2 Diabetes on monotherapy

Each tablet of Glizid-MV contains:

• Gliclazide – 40 mg / 60 mg (varies by formulation)

• Metformin Hydrochloride – 500 mg / 850 mg

• Voglibose – 0.2 mg / 0.3 mg

(Strengths may differ based on prescription and region.)

• Type 2 Diabetes Mellitus (Non-Insulin Dependent Diabetes)

• Uncontrolled diabetes not managed by diet or single-drug therapy

• Patients requiring combination therapy to achieve target glucose levels

• Dosage is individualized based on blood glucose levels and medical advice.

• Usually taken orally once or twice daily before meals.

• Regular blood sugar monitoring is recommended.

• Do not skip doses or discontinue use without consulting a doctor.

• Gliclazide increases insulin secretion.

• Metformin decreases hepatic glucose output and improves insulin utilization.

• Voglibose slows carbohydrate absorption, preventing postprandial glucose spikes.

Their combined action ensures stable, round-the-clock blood glucose control.

The Gliclazide + Metformin + Voglibose combination is marketed globally under several brand names, including Glizid-MV, Glimisave-MV, Glycomet Trio, and Triohale formulations for diabetic care.

Orders for Glizid-MV Tablets are processed within 48 hours of payment confirmation. All products are securely packaged to maintain quality during international shipping.

We ensure fast and reliable delivery through DHL, FedEx, UPS, EMS, Aramex, India Post, and Delhivery with real-time tracking updates.

• Wire / Bank Transfer

• Telegraphic Transfer (TT)

• Western Union

• Ria Money Transfer

This information is provided for B2B trade and educational purposes only. Glizid-MV Tablets should be used strictly under the guidance of a qualified healthcare professional.

Prices may vary depending on order size, region, and packaging specifications. For bulk purchases, distributor pricing, or export inquiries, please contact the supplier directly through verified channels.